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Abstract
Background: Phospholipases A2 (PLA2s) are abundant components of snake venoms that have been extensively
studied due to their pharmacological and pathophysiological effects on living organisms. This study aimed to assess
the antitumor potential of BthTX-I, a basic myotoxic PLA2 isolated from Bothrops jararacussu venom, by evaluating
in vitro processes of cytotoxicity, modulation of the cell cycle and induction of apoptosis in human (HL-60 and
HepG2) and murine (PC-12 and B16F10) tumor cell lines.
Methods: The cytotoxic effects of BthTX-I were evaluated on the tumor cell lines HL-60 (promyelocytic leukemia),
HepG2 (human hepatocellular carcinoma), PC-12 (murine pheochromocytoma) and B16F10 (murine melanoma)
using the MTT method. Flow cytometry technique was used for the analysis of cell cycle alterations and death
mechanisms (apoptosis and/or necrosis) induced in tumor cells after treatment with BthTX-I.
Results: It was observed that BthTX-I was cytotoxic to all evaluated tumor cell lines, reducing their viability in 40 to
50 %. The myotoxin showed modulating effects on the cell cycle of PC-12 and B16F10 cells, promoting delay in
the G0/G1 phase. Additionally, flow cytometry analysis indicated cell death mainly by apoptosis. B16F10 was
more susceptible to the effects of BthTX-I, with ~40 % of the cells analyzed in apoptosis, followed by HepG2
(~35 %), PC-12 (~25 %) and HL-60 (~4 %).
Conclusions: These results suggest that BthTX-I presents antitumor properties that may be useful for developing
new therapeutic strategies against cancer.
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Background
According to the World Health Organization, cancer is one
of the leading causes of morbidity and mortality worldwide.
Cancer is a generic term for a large group of diseases that
may affect any part of the body [1]. These diseases are char-
acterized by uncontrolled growth and spread of abnormal
cells, and may be caused by external factors (smoking,
infectious organisms, radiation and chemical products)
and internal factors (inherited or metabolic mutations,
hormones and immune conditions) [2].
A correct diagnosis of cancer is essential for appropriate
and effective treatment, because each cancer type requires
specific treatments that may include surgery, radiotherapy
and/or chemotherapy. Nonetheless, chemotherapy is flawed
especially considering that no chemotherapeutic agent
available acts exclusively on tumor cells, affecting also
many types of normal body cells and leading to several
undesirable effects [2, 3].
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Currently there is great medical and scientific interest
in the investigation of natural products for therapeutic
purposes, in search of new molecules that could be used
as antitumor agents with fewer side effects than the usual
chemotherapy, or serve as molecular models for the
development of more effective drugs against malignant
tumors [4, 5].
In recent years, studies on snake venoms and their
components have demonstrated the antitumor effects of
different toxins [6–8]. The focus of these researches has
been the understanding of the mechanisms of action of
toxins on different types of tumors. It is known that the
cytotoxicity induced by animal venoms is mainly related
to changes in the cellular metabolism of cells, especially
tumorous ones, however, the mechanisms of action of these
toxins are still to be clarified, which makes them target of
many studies with interest in their therapeutic potential [8].
Some phospholipases A2 (PLA2s) have been described
to possess antitumor and antiangiogenic properties [9–11].
PLA2s are enzymes of great scientific interest due to their
involvement in several human inflammatory diseases and
in envenomations by snakes and bees. In addition, PLA2s
present important effects on lipid membranes and are
related to the formation of various substances involved
in numerous biological activities, such as prostaglandins,
prostacyclins, thromboxanes and leukotrienes [12, 13].
Myotoxins are PLA2 homologues that present a substi-
tution of the aspartic acid residue at position 49 (Asp49)
by a lysine (Lys49), with changes in their calcium binding
site. These variations are related to the low or no catalytic
activity presented by these molecules [14]. Nevertheless,
myotoxic PLA2s have diverse biological effects, such as
myotoxicity, edema, anticoagulation, neurotoxicity, indir-
ect hemolysis, cytotoxicity, and also antibacterial, antiviral
and antiparasitic activities [15].
Bothropstoxin-I (BthTX-I) is a single chain protein of
13.7 kDa and pI 8.2, with 121 amino acid residues and 7
disulfide bonds, isolated from Bothrops jararacussu snake
venom [16]. This basic myotoxin showed action on the
gastrocnemius muscle of mice and cytotoxicity in murine
muscle cells (C2C12) and also had its cytotoxic effects
evaluated both in vitro and in vivo on different tumor cell
lines such as Jurkat, SKBR3, B16F10 and S180, showing
promising antitumor properties [17, 18].
Considering these previous findings on BthTX-I and
the wide variety of cytotoxic effects presented by snake
toxins, additional studies using different tumor cell lines
are necessary in order to increase the knowledge of the
antitumor and biotechnological potential of this B. jarara-
cussu myotoxin. Thereby, this study aimed to evaluate the
in vitro effects of BthTX-I on human (HL-60 and HepG2)
and murine (PC-12 and B16F10) tumor cell lines by
assessing its induced cytotoxicity, cell cycle alterations
and death mechanisms.
Methods
Materials
Toxin
BthTX-I was isolated from Bothrops jararacussu venom
according to the methodology described by Cintra et al.
[19]. The lyophilized protein was stored at −20 °C and
solubilized in phosphate buffered saline (PBS) immedi-
ately before its use in the tests.
Cell lines
HL-60 (CCL-240, promyelocytic leukemia), HepG2 (HB-
8065, human hepatocellular carcinoma), PC-12 (CRL-1721,
murine pheochromocytoma) and B16F10 (CRL-6475,
murine melanoma) tumor cell lines were obtained from
ATCC (American Type Culture Collection, USA).
Methods
Cell culture
Cells were grown in monolayer in 25 cm2 flasks. HL-60
cells were cultured in 5 mL of RPMI culture medium
(Gibco 31800–022, USA) supplemented with 10 % fetal
bovine serum (FBS, Gibco 12657, USA) and 1 % antibiotic
(streptomycin and penicillin, P4333 Sigma, USA). PC-12
cells were cultured in 5 mL of RPMI supplemented
with 15 % fetal equine serum (Gibco 26050–088, New
Zealand), 5 % FBS and 1 % antibiotic. B16F10 and HepG2
cells were grown in DMEM culture medium (Gibco
31600–034, USA) also supplemented with 10 % FBS and
1 % antibiotic. The vials containing the cells were incu-
bated at 37 °C in a humidified incubator containing 5 %
CO2, until reaching a state of confluence (~5 × 10
6 cells)
when they require subculture. The tests with BthTX-I
were performed with cells between the 3rd and 6th day of
subculture. Cell viability tests using the Trypan blue dye
were performed before any experimentation to ensure the
accuracy of the results.
Cytotoxic assays using MTT
For the cytotoxicity assay, tumor cells (HL-60, PC-12,
HepG2 or B16F10) were seeded into 96-well plates,
followed by incubation for 24 h at 37 °C in a humidified
incubator containing 5 % CO2. After this period, the
cells were treated with 50 μL of PBS (negative control)
or 50 μL of BthTX-I samples at different concentrations
(5; 10; 25; 50 or 100 μg/mL). Experimental positive con-
trol received 50 μL of a cisplatin solution at 1 mg/mL
(Incel, Darrow®), which is an antineoplastic agent that
binds to DNA, inducing structural changes and, conse-
quently, apoptosis. After treatment, the wells received
20 μL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide] (Sigma M2128, USA) (500 μg/mL,
final concentration) and plates were incubated for 3 h at
37 °C and 5 % CO2. Then, plates were centrifuged at 900 g
for 5 min and then inverted to discard the supernatant,
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followed by addition of 100 μL of DMSO (Sigma D2650,
USA) to each well. The plates were kept under stirring
until complete dissolution of crystals (~20 min) and then
the absorbance at 570 nm was determined in a Powerwave
XS2 microreader (Biotek) [20].
Cell cycle analysis
Tumor cells (HL-60, PC-12, HepG2 or B16F10) were
plated into 24-well plates (1 × 106 cells/well), followed by
incubation for 24 h at 37 °C in a humidified incubator
containing 5 % CO2. After this period, the cells were
treated with 50 μL of PBS (negative control) or 50 μL of
BthTX-I samples at different concentrations (5; 10; 25;
50 or 100 μg/mL). After 24 h of treatment, cells were
transferred to flow cytometry tubes and centrifuged at
900 g for 5 min, supernatant was discarded and pellet re-
suspended in 1 mL of PBS. Then, cells were centrifuged
again, the supernatant was discarded, the pellet resus-
pended in 100 μL of cold PBS and 2 mL of cold 70 %
ethanol and the samples were stored at −20 °C for 24 h.
At the end of this period, the tubes were centrifuged, the
supernatant discarded and the pellet was resuspended in
300 μL of cold PBS with 10 μL of RNase (10 mg/mL)
and incubated for 30 min at 37 °C. Immediately after the
incubation, samples were placed in an ice bath with 164 μL
of HFS (hypotonic fluorescence solution, a reagent that
measures the amount of DNA in the cell and defines its cell
cycle position) and incubated on ice for 1 h, followed by
analysis of 10,000 events in a FACSCanto flow cytometer
(Becton Dickinson, USA). The files generated by the equip-
ment were read in the FlowJo 7.6.1 software for the analysis
of cell division phases: G0/G1, S and G2/M. The results
were expressed as the percentage of cells in each phase of
the cycle [6].
Analysis of apoptosis/necrosis by flow cytometry
The assessment of the apoptotic and necrotic effects in-
duced by BthTX-I on different tumor cell lines (HL-60,
PC-12, HepG2 or B16F10) was determined by flow cy-
tometry, using a kit containing annexin V FITC and
propidium iodide (PI) [21]. The population of necrotic
cells is marked with PI (PI+), while the cells in apop-
tosis are marked with annexin V FITC (AV+) and the
population of both necrotic and apoptotic cells is marked
as PI+/AV+.
Tumor cells were plated into 24-well plates (5 × 105
cells/well), followed by incubation for 24 h at 37 °C in
a humidified incubator containing 5 % CO2. After this
period, the cells were treated with 50 μL of PBS (nega-
tive control) or 50 μL of BthTX-I samples at different
concentrations (5; 10; 25; 50 or 100 μg/mL). Experimental
positive control received 50 μL of a cisplatin solution at
1 mg/mL. After 24 h of treatment, cells were transferred
to flow cytometry tubes, and centrifuged at 900 g for
5 min, supernatant was discarded and pellet resuspended in
1 mL of PBS. The same process was repeated, this time
with addition of 300 μL of 1X annexin V to the resus-
pended pellet and 5 μL of FITC-annexin V to each tube.
The samples were incubated for 15 min in ice, adding 1 μL
of propidium iodide (PI) immediately after incubation,
followed by analysis of 10,000 events in a FACSCanto flow
cytometer (Becton Dickinson, USA) using Diva software.
Statistical analysis
Results were analyzed by the software Graph Pad Prism 5
using the method one-way ANOVA and Tukey’s post-test,
considering values of p < 0.05 as significant. All treatments
were compared to the negative control (PBS).
Results
Evaluation of the cytotoxicity induced by BthTX-I
The antitumor activity of BthTX-I was assessed by treat-
ing tumor cell lines with different concentrations of the
myotoxin. For HL-60, it was observed that the cell via-
bility after treatment with BthTX-I was of approximately
80 % for the lowest concentration evaluated (5 μg/mL),
while at the concentrations of 10, 25, 50 and 100 μg/mL,
cell viabilities of 46; 36; 40 and 38 %, respectively, were
observed (Fig. 1 – a). For HepG2, BthTX-I concentrations
from 5 to 25 μg/mL led to cell viabilities of approximately
40 %, whereas at the concentrations of 50 and 100 μg/mL,
the values of viability observed were of 35 % and 30 %, re-
spectively (Fig. 1 – b). For PC-12, cell viability ranged from
40 to 60 %, with lowest values observed after treatment
with BthTX-I at the concentration of 25 μg/mL (Fig. 1 – c).
B16F10 cells showed around 40 % cell viability at all
concentrations tested (Fig. 1 – d).
Cell cycle kinetics analysis
The cell cycle kinetics analysis was performed in order
to detect the role of BthTX-I in the cell division process
of tumor cells. HL-60 and HepG2 cells treated with dif-
ferent concentrations of the toxin showed distribution in
all three phases of the cell cycle (G0/G1, S, G2/M), with
no significant differences (p < 0.05) in comparison with
the negative control (PBS). Around 70 % of the HL-60
cells remained in G0/G1, 15 % in S and 15 % in G2/M
phases (Fig. 2 – a), while 70 % of HepG2 cells remained in
G0/G1, 20 % in S and 10 % in G2/M phases (Fig. 2 – b).
PC-12 and B16F10 cells treated with different concen-
trations of BthTX-I showed delayed cell cycles, with an
increased number of cells in the G0/G1 phase, followed
by a reduction in the percentage of cells in the S phase
and an absence of cells in the G2/M phase. The increase
in the percentage of PC-12 cells in the G0/G1 phase,
compared with the negative control, was of ~16 % for
the treatments with 10; 25 and 50 μg/mL of BtTX-I, and
of 26 % with the toxin at 100 μg/mL (Fig. 2 – c). This
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increase for B16F10 cells was of approximately 24 %
after treatment with BthTX-I at all the concentrations
evaluated (Fig. 2 – d).
Analysis of the apoptotic/necrotic effects of BthTX-I
All concentrations of BthTX-I induced apoptosis/necro-
sis (PI+/AV+) in leukemic cells (HL-60), with the highest
percentage of PI+/AV+ cells (~20 %) observed at the
concentrations of 50 and 100 μg/mL. There was also a
small percentage of cells that were only in necrotic process
(1-5 %) at all the concentrations evaluated (Fig. 3 – a).
The treatment of HepG2 cells with BthTX-I at the
concentrations of 25 and 50 μg/mL induced apoptosis/
necrosis (PI+/AV+) in 24 % of the cell population, and
apoptosis (AV+) in 44 and 34 % of cells, respectively. At
the concentration of 100 μg/mL, 16 % of cells were in
the process of necrosis (PI+), 40 % in apoptosis/necrosis
(PI+/AV+) and 28 % in apoptosis (AV+) (Fig. 3 – b).
BthTX-I at the concentrations of 25 and 50 μg/mL
induced about 10 % of PC-12 cell death by apoptosis/
necrosis and 15 % by apoptosis. The concentration of
100 μg/mL promoted apoptosis in approximately 20 %
of cells (Fig. 3 – c).
The treatment of B16F10 cells with different concen-
trations of BthTX-I (25, 50 and 100 μg/mL) promoted a
high percentage of cell death by apoptosis (AV+) (30
to 40 %), with lower percentages of cells exclusively in
the processes of necrosis (3, 8 and 4 %, respectively)
or apoptosis (~5 %) (Fig. 3 – d).
Discussion
Many toxins isolated from snake venoms have been used
as tools for understanding different pathophysiological
events, since these proteins present several biological ef-
fects such as antiparasitic, antimicrobial and antitumor
activities [22–24]. In that context, snake venom PLA2s
of both acidic and basic character, and also synthetic
peptides derived from homologous PLA2s, have been
extensively studied due to their wide variety of pharmaco-
logical effects, including their antitumor and antiangiogenic
properties [25–27].
In recent years, PLA2s have been investigated as tools
for better understanding the mechanisms related to cancer.
This class of toxins seems to act directly on the metabolism
of phospholipid membranes, promoting changes in the
lipid biosynthesis and deregulation of lipogenesis in dif-
ferent cell lines, including tumorous ones [28].
In the present study, BthTX-I induced significant cytotox-
icity in all tested tumor cell lines. In general, all concentra-
tions of the myotoxin inhibited the viability of HL-60,
HepG2, PC-12 and B16F10 cells in 50 to 60 %. These re-
sults are consistent with many others which have shown
that these toxins have the ability to induce death of various
tumor and non-tumor cell lines [11, 29, 30].
Fig. 1 Cell viability of the tumor cell lines HL-60 (a), HepG2 (b), PC-12 (c) and B16F10 (d) after treatment with BthTX-I. The cytotoxicity was
evaluated by the MTT method 24 h after treatment of tumor cells with BthTX-I (5–100 μg/mL). Results expressed as mean ± SD of three independent
experiments (n = 3). Statistically significant differences (p < 0.05) were labeled with * (in comparison to PBS). PBS (negative control); Cisp (cisplatin,
positive control)
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Cisplatin (Incel, Darrow®) was used in the present
study as a positive control of cytotoxicity, being able to
promote death of all tumor cell lines evaluated, with
lower effects on B16F10 cells. It is an inorganic platinum
compound that binds to DNA and provokes structural
changes and inhibition of transcription and replication,
thus inducing apoptosis. Considering its cytotoxic effects,
cisplatin is widely used as an antineoplastic agent in the
treatment of several types of cancer [31].
Gebrim et al. [18] evaluated the in vitro antitumor ac-
tivity of BthTX-I using tumor cell lines such as Jurkat,
SKBR3 and B16F10, and showed that the native protein
presented 75 to 90 % cytotoxicity on these tumor cell
lines. Regarding in vivo experiments, injection of BthTX-I
modified with p-bromophenacyl bromide (BPB, an agent
that inhibits PLA2s by covalently binding to their active
site) in mice transplanted with S180 tumor cells reduced
30 % of the tumor size on the 14th day and 76 % on the
60th day, when compared to the untreated control group.
These findings are in accordance with other studies that
suggested that the antitumor properties of PLA2s are inde-
pendent of their catalytic activity [32, 33].
De Moura et al. [11] evaluated the cytotoxic effect of
three PLA2s isolated from B. mattogrossensis venom,
BmatTX-I (Lys49), BmatTX-II (Lys49) and BmatTX-III
(Asp49) on Jurkat and SKBR-3 tumor cells. These authors
observed that the Lys49 myotoxins were more cytotoxic
than the Asp49 PLA2 to both tumor cells. Similar to that
observed for BthTX-I, the toxins BmatTX-I and BmatTX-II
at a concentration of 100 μg/mL inhibited the cell viability
of Jurkat cells in approximately 50 %. Equivalent effects
were observed when Jurkat cells were treated with 100 μg/
mL of two acidic Asp49 PLA2s, BmooTX-I from B. moojeni
venom and MTX-I from B. brazili venom [34, 35]. BthA-I-
PLA2, an acidic PLA2 from B. jararacussu venom, also
showed potential antitumor effects on Jurkat, SKBR-3 and
Ehrlich ascites tumor (EAT) cells, with the enzyme at
100 μg/mL promoting death of 50 to 70 % of the tumor
cells [36].
Studies suggest that several biological effects of the
myotoxins are related to the interaction of their C-ter-
minal region with cell membranes, which explains the syn-
thesis of peptides derived from this region described in
different studies [18, 35, 37]. The C-terminal region is usu-
ally described as capable of disrupting the hydrophilic
matrix of membranes, opening pores and allowing the
entrance of the toxins into the intracellular medium [38].
Investigations involving the mechanisms of action of
snake venom toxins on tumor cells are still scarce in the
literature. However, some suggestions of mechanisms have
Fig. 2 Assessment of cell cycle progression of the tumor cell lines HL-60 (a), HepG2 (b), PC-12 (c) and B16F10 (d) treated with BthTX-I using flow
cytometry. Tumor cells were treated with BthTX-I at different concentrations (5 to 100 μg/mL). Cells treated with PBS were used as negative
control (PBS). The cells were fixed with ethanol and stained with propidium iodide present in the HFS solution. G0/G1: resting/preparation for
synthesis; S: DNA synthesis; G2/M: preparation for mitosis. Results expressed as mean ± SD of three independent experiments (n = 3). Statistically
significant differences (p < 0.05) are labeled with * (in comparison with G0/G1 phase of PBS)
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been proposed for components such as L-amino acid
oxidases (LAAOs), which have been described as potent
cytotoxic agents. Several studies attributed the cytotoxic ef-
fects of LAAOs mainly to the release of hydrogen peroxide
to the medium, resulting in oxidative stress and conse-
quently in cell death [7, 39].
The effect of cytotoxic agents can be evaluated by cell
cycle analyses. The cell cycle is a series of continuous and
repetitive processes that occur during a normal cell division
[40]. The cycle is divided into interphase and mitosis. The
interphase is further subdivided into the phases G0, G1, S
and G2, in which the DNA duplication and preparation of
cells for the next stage occurs. The mitosis is characterized
by the cell division process itself [40, 41].
Flow cytometry experiments were performed for the
cell cycle analyses, with the purpose of evaluating the ef-
fects of BthTX-I in the process of cell division. Nuclear
DNA of cells was stained by a specific fluorochrome (PI),
allowing its quantification and reflecting the position of
cells in the cell cycle. BthTX-I was not able to induce any
significant change in the cell cycle of HL-60 and HepG2
tumor cells. Conversely, the toxin caused a delay in the
G0/G1 phase of the cell cycle of PC-12 and B16F10 tumor
cells. The fact that the myotoxin promoted delay in the
cell cycle indicates that it disrupts the mitotic progression
and hence a smaller number of cells are doubled, which
would implicate an important antitumor mechanism.
Although few studies have been conducted with snake
venom toxins regarding their effects on the cell cycle
progression, some other snake toxins were also described
as able to promote delay of the cell cycle in the G0/G1
phase [6, 42]. Checkpoint proteins (CKI’s, CDK’s and
CHK) are probably preventing these cells from leaving
the G0/G1 phase. The CKI’s are able to suspend the
cell cycle at any sight of DNA damage, directing the cells
to repair systems. The cell cycle only continues when the
Fig. 3 Assessment of apoptotic/necrotic effects of BthTX-I on the tumor cell lines HL-60 (a), HepG2 (b), PC-12 (c) and B16F10 (d) by flow cytometry.
Tumor cells were treated with BthTX-I at different concentrations (25, 50 or 100 μg/mL). Cisplatin (Cisp, positive control) was used as a reference for the
induction of apoptosis and cells treated only with PBS were used as negative control. The population of necrotic cells was labeled with propidium
iodide (PI+), apoptosis was labeled with FITC-annexin V (AV+) and population of necrotic and apoptotic cells was labeled with PI+/AV+.
Results expressed as mean ± SD of three independent experiments (n = 3). Statistically significant differences (p < 0.05) were labeled with * (values of
PI+/AV+ compared with PBS); # (values of AV+ compared with PBS) or + (values of PI+ compared with PBS)
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damaged DNA is restored, and in case the repair systems
are unable to correct the damage, cell death processes are
induced [43].
Exposure to toxic agents can trigger cell death by pro-
cesses of apoptosis or necrosis, and both processes occur
depending on the intensity and duration of exposure.
Necrosis is an accidental form of cell death in which a
failure in the cell homeostasis occurs after the cell is
damaged, leading to an inflammatory process [44–46].
Apoptosis is a controlled form of cell death, defined by a
number of biochemical and morphological characteristics,
such as the exposure of phosphatidylserine to the outside
of the plasma membrane, the cell nucleus condensation
and the cleavage of chromatin (DNA) in oligonucleosomal
fragments [47].
The apoptosis-inducing ability of BthTX-I was assessed
by flow cytometry using annexin V conjugated to fluores-
cein, which acts as a marker for the phosphatidylserine ex-
posed on cells undergoing apoptosis stage. The necrotic
effect was analyzed by staining with propidium iodide (PI),
which marks the nucleic acid of dead cells.
Our results showed that different BthTX-I concentra-
tions induced tumor cell death by processes of apoptosis
and/or necrosis. The myotoxin mainly induced apoptosis
(AV+) in PC-12 and B16F10 cells at all concentrations
tested (25, 50 or 100 μg/mL), which suggests this process
as the predominant cell death mechanism induced by
BthTX-I on these murine tumor cells. Regarding hu-
man tumor cell lines (HL-60 and HepG2), apparently
distinct death mechanisms could be observed: the percent-
age of HepG2 cells in apoptosis (AV+) was practically
equal to those in apoptosis/necrosis (PI+/AV+), while for
HL-60 cells, the major percentage of cells was marked as
PI+/AV+, indicating death mechanisms related to both
apoptosis and necrosis.
These findings corroborate the data obtained for other
enzymes isolated from snake venoms, which promoted
death in various cell lines by different mechanisms, such
as apoptosis and necrosis [48, 49]. Several factors may
determine whether cells go into apoptosis or necrosis,
such as the toxin concentration, the ability of cells to
manage local membrane perturbations and the meta-
bolic status of cells [50]. Mora et al. [9] evaluated the
induction of apoptosis and necrosis by a Lys49 PLA2
homologue from Bothrops asper snake venom in a
lymphoblastoid cell line, and concluded that the en-
zyme was able to induce significantly different effects
depending on the concentration of toxin used.
Conclusion
BthTX-I was shown to be cytotoxic for both human
(HepG2 and HL-60) and murine (PC-12 and B16F10)
tumor cell lines by inducing cell death mechanisms of
apoptosis and/or necrosis. Additionally, BthTX-I was able
to promote delay in the G0/G1 phase of the cell cycle
of murine tumor cells. The results revealed important
functional characteristics of this myotoxin isolated from B.
jararacussu venom, demonstrating a remarkable antitumor
potential still little explored. Studies on the mechanisms of
action of BthTX-I are very important so that it may serve
as a model for the development of new therapeutic
agents to treat various human diseases such as cancer
in the future.
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